Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip J Stephens

Showing results (41-50 of 168) with videos related to

Pageof 17
Sort By:
The Oncologist|December 7, 2014
Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of originJuliann Chmielecki, Jeffrey S Ross, Kai Wang, et al.
The Oncologist|May 7, 2016
Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical TrialsJames H Suh, Adrienne Johnson, Lee Albacker, et al.
Oncotarget|June 17, 2015
Identification and characterization of RET fusions in advanced colorectal cancerAnne-France Le Rolle, Samuel J Klempner, Christopher R Garrett, et al.
Journal of Medicinal Chemistry|August 18, 2006
Calcium channel antagonists discovered by a multidisciplinary approachEmanuele Carosati, Gabriele Cruciani, Alberto Chiarini, et al.
JCO Precision Oncology|February 17, 2022
Response of a Metastatic Breast Carcinoma With a Previously Uncharacterized ERBB2 G776V Mutation to Human Epidermal Growth Factor Receptor 2-Targeted TherapyYakov Chudnovsky, Runjun D Kumar, Alexa B Schrock, et al.
Breast Cancer Research and Treatment|January 15, 2016
Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling studyJeffrey S Ross, Laurie M Gay, Sahar Nozad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2014
Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapySiraj M Ali, R Katherine Alpaugh, Sean R Downing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2011
Novel chromosomal rearrangements and break points at the t(6;9) in salivary adenoid cystic carcinoma: association with MYB-NFIB chimeric fusion, MYB expression, and clinical outcomeYoshitsugu Mitani, Pulivarthi H Rao, P Andrew Futreal, et al.
European Journal of Cancer (Oxford, England : 1990)|March 24, 2015
Comparative analysis of primary tumour and matched metastases in colorectal cancer patients: evaluation of concordance between genomic and transcriptional profilesStéphane Vignot, Céline Lefebvre, Garrett M Frampton, et al.
The American Journal of Dermatopathology|January 4, 2017
Next-Generation Sequencing Reveals Pathway Activations and New Routes to Targeted Therapies in Cutaneous Metastatic MelanomaJ Andrew Carlson, Jose Candido Caldeira Xavier, Ashley Tarasen, et al.
Pageof 17

Showing results (41-50 of 168) with videos related to

Sort By:
Pageof 17
The Oncologist|December 7, 2014
Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of originJuliann Chmielecki, Jeffrey S Ross, Kai Wang, et al.
The Oncologist|May 7, 2016
Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical TrialsJames H Suh, Adrienne Johnson, Lee Albacker, et al.
Oncotarget|June 17, 2015
Identification and characterization of RET fusions in advanced colorectal cancerAnne-France Le Rolle, Samuel J Klempner, Christopher R Garrett, et al.
Journal of Medicinal Chemistry|August 18, 2006
Calcium channel antagonists discovered by a multidisciplinary approachEmanuele Carosati, Gabriele Cruciani, Alberto Chiarini, et al.
JCO Precision Oncology|February 17, 2022
Response of a Metastatic Breast Carcinoma With a Previously Uncharacterized ERBB2 G776V Mutation to Human Epidermal Growth Factor Receptor 2-Targeted TherapyYakov Chudnovsky, Runjun D Kumar, Alexa B Schrock, et al.
Breast Cancer Research and Treatment|January 15, 2016
Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling studyJeffrey S Ross, Laurie M Gay, Sahar Nozad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2014
Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapySiraj M Ali, R Katherine Alpaugh, Sean R Downing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2011
Novel chromosomal rearrangements and break points at the t(6;9) in salivary adenoid cystic carcinoma: association with MYB-NFIB chimeric fusion, MYB expression, and clinical outcomeYoshitsugu Mitani, Pulivarthi H Rao, P Andrew Futreal, et al.
European Journal of Cancer (Oxford, England : 1990)|March 24, 2015
Comparative analysis of primary tumour and matched metastases in colorectal cancer patients: evaluation of concordance between genomic and transcriptional profilesStéphane Vignot, Céline Lefebvre, Garrett M Frampton, et al.
The American Journal of Dermatopathology|January 4, 2017
Next-Generation Sequencing Reveals Pathway Activations and New Routes to Targeted Therapies in Cutaneous Metastatic MelanomaJ Andrew Carlson, Jose Candido Caldeira Xavier, Ashley Tarasen, et al.
Pageof 17